Prospective analyses of lung cancer patients have revealed that individuals harboring TP53 or KRAS mutations, and especially patients harboring mutations in both of these genes, can attain significant benefits from PD-1 inhibitor treatment31. The gene discussed is KRAS; the disease is lung carcinoma.